Personalized vaccine for patients with pancreatic cancer after surgery
Part of Cancer clinical trials.
This trial offers an experimental personalized vaccine for people with pancreatic cancer who have already had surgery and standard treatment. The vaccine is designed to help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You have been diagnosed with pancreatic ductal adenocarcinoma and had it surgically removed
- You have completed standard chemotherapy or radiation after surgery (or stopped due to severe side effects)
- Your cancer has not come back or spread
- You must be in generally good health (able to care for yourself or only need help with strenuous activity)
- Tumor tissue must be available for testing to create a personalized vaccine
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized neoantigen vaccine given along with an anti-PD1 drug (pembrolizumab) and chemotherapy after surgery for pancreatic cancer. The goal is to see if this combination can help prevent the cancer from coming back.
This study tests a personalized vaccine made from your own tumor, combined with a drug that helps your immune system fight cancer cells. The goal is to see if this approach can help prevent your pancreatic cancer from coming back after surgery.
This early-stage trial tests a personalized immune “vaccine” made from dendritic cells, given alongside standard chemotherapy for pancreatic cancer that may be removable by surgery (resectable or borderline resectable). If it works, it may help your immune system better recognize and attack the cancer around the time of treatment.
This trial tests a personalized vaccine made from your own tumor's genetic information. The vaccine is given after surgery to try to train your immune system to fight any remaining cancer cells and reduce the chance of the cancer coming back.
This early-phase trial tests a personalized cancer vaccine made from your tumor, along with pembrolizumab, to help the immune system attack advanced pancreatic cancer. It may be an option if your cancer has specific immune “targets” and if you meet several health, lab, and infection requirements.
This study tests a personalized vaccine made from your tumor's unique markers. It aims to help your immune system attack pancreatic cancer that has spread or returned.
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.